| Patient | Jesse Owens |
|---|---|
| Date of birth | 1913-09-12 |
| Identifiers | MRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319 |
| Document date | 1979-06-24 |
| Author | Clarence Whitfield-Arroyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed. [S]
Mr. Owens comes before his second cycle, three weeks after the first. He has not smoked since the morning of cycle 1. Varenicline gave him mild nausea for the first week, which settled by taking it after food; his dreams are vivid but not upsetting. After cycle 1 he was tired for four days and mildly nauseated for two, needing ondansetron twice. He has had no diarrhea, rash, cough beyond his usual, breathlessness, headache, or yellowing. He has been to five pulmonary rehabilitation sessions and walks most mornings. The hepatitis and HIV tests before cycle 1 were negative. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Since the last visit | Cycle 1 three weeks ago; pulmonary rehabilitation started |
| Tobacco | Abstinent for three weeks on varenicline |
| Side effects | Fatigue for four days and mild nausea for two after cycle 1; no immune-related symptoms |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for four days after cycle 1; weight 75.8 kg; no fever |
| Gastrointestinal | Positive | Mild nausea for two days after cycle 1 and in the first week of varenicline; no diarrhea |
| Respiratory | Negative | Morning cough less since stopping smoking; no breathlessness |
| Integumentary | Negative | No rash or itching |
| Endocrine | Negative | No heat or cold intolerance or unusual thirst |
| Neurological | Negative | No numbness or tingling; no headache |
| Psychiatric | Negative | Mood good; vivid dreams on varenicline; PHQ-2 0 |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 1979-05-26 to 1979-06-01 | completed | S |
| Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse | 1 mg twice daily after food | Oral route | 1979-06-02 | active | S |
| Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 1979-05-26 to 1979-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 1979-05-26 to 1979-05-26 | completed | S |
| Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose | 4 mg twice daily for three days around each cycle | Oral route | 1979-06-02 to 1979-07-16 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy | 8 mg every 8 hours as needed | Oral route | 1979-06-03 to 1979-07-31 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-06-24 | Body height | 178 | cm | S |
| 1979-06-24 | Body weight | 75.8 | kg | S |
| 1979-06-24 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 1979-06-24 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1979-06-24 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1979-06-24 | Heart rate | 74 | /min | S |
| 1979-06-24 | Respiratory rate | 16 | /min | S |
| 1979-06-24 | Body temperature | 36.6 | Cel | S |
| 1979-06-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-06-24 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1979-06-24 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-06-24 | Neutrophils [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-06-24 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-06-24 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-06-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-06-24 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
| 1979-06-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 1979-06-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 8-48 U/L | Normal | S |
| 1979-06-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-06-24 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1979-06-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1979-06-24 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 1979-06-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 75.8 kg; blood pressure 126/78, pulse 74; oxygen saturation 96 percent |
| Mouth | No ulcers |
| Respiratory | Clear; no crackles |
| Skin | No rash |
| Neurological | Light touch and vibration normal in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | active | confirmed | F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 13.6, white cells 6.9, neutrophils 4.1, platelets 214 |
| Laboratory | Immune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucose | Before each immunotherapy infusion | Completed today | TSH 2.6, free T4 1.1; ALT 28, AST 25, bilirubin 0.5; creatinine 1.0, eGFR 84; glucose 101 non-fasting the morning after dexamethasone |
| Laboratory | Morning cortisol | Baseline and before each immunotherapy infusion (CMID); for symptoms | Deferred | Missed: the CMID schedule calls for cortisol before each infusion, but the cycle 2 order set did not include it and it was not drawn. No harm is expected: he has no fatigue beyond the days after chemotherapy, no low blood pressure, low sodium or dizziness. Corrective action: cortisol added to the standing order set for cycle 3 and to the blood tests before surgery |
| Examination | Immune-related adverse event symptom review (diarrhea, rash, cough, breathlessness, headache, jaundice) | Every visit on immunotherapy | Completed today | None |
| Examination | Peripheral neuropathy after platinum | Every visit during and after platinum therapy | Completed today | No symptoms; light touch and vibration normal |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent three weeks on varenicline |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-2 0 |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Morning cough lighter since stopping smoking; no breathlessness |
| Self-management | Pulmonary rehabilitation (prehabilitation) | Before and after lung resection | Completed today | Five sessions attended |
| Imaging | Response imaging | After the three cycles before surgery | Due | Restaging CT after cycle 3 |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)
Follow-up: Cycle 3 in three weeks. Thoracic surgery review next week. Visit with restaging CT after cycle 3. Call the oncology line for any warning sign. Next scheduled visit 1979-08-05: after three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation. [S]